LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease

Naka, Tetsuji; Fujimoto, Minoru

doi:10.1080/13497413.2018.1481582

Cited by 51 publications

(72 citation statements)

References 13 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LRG1 is another pro-inflammatory factor induced by IL-6 (Shirai et al, 2009) , which is known to promote angiogenesis and cell proliferation, while inhibiting apoptosis (Meng et al, 2016;Naka and Fujimoto, 2018;Wang et al, 2013) . Some recent findings indicate its role in promoting skin fibrosis and lung fibrosis in Transforming Growth Factor beta (TGF-β)-mediated fashion (Gao et al, 2019;Honda et al, 2017) .…”

Section: Plasma Proteomes Provide Insights Into the Virulence Mechanimentioning

confidence: 99%

“…Leucine-Rich Alpha-2-Glycoprotein LRG1 expression is induced by IL-6 (Shirai et al, 2009) , which is elevated in severe COVID-19 (Ruan et al, 2020) . LRG1 promotes angiogenesis (Wang et al, 2013) and has been reported to be associated with local inflammation (Naka and Fujimoto, 2018) . LRG1 is known to promote lung fibrosis (Honda et al, 2017) .…”

Section: Supplementary Informationmentioning

confidence: 99%

See 1 more Smart Citation

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

Messner

Demichev

Wendisch

et al. 2020

Preprint

View full text Add to dashboard Cite

The COVID-19 pandemic is an unprecedented global challenge. Highly variable in its presentation, spread and clinical outcome, novel point-of-care diagnostic classifiers are urgently required. Here, we describe a set of COVID-19 clinical classifiers discovered using a newly designed low-cost high-throughput mass spectrometry-based platform. Introducing a new sample preparation pipeline coupled with short-gradient high-flow liquid chromatography and mass spectrometry, our methodology facilitates clinical implementation and increases sample throughput and quantification precision. Providing a rapid assessment of serum or plasma samples at scale, we report 27 biomarkers that distinguish mild and severe forms of COVID-19, of which some may have potential as therapeutic targets. These proteins highlight the role of complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling upstream and downstream of Interleukin 6. Application of novel methodologies hence transforms proteomics from a research tool into a rapid-response, clinically actionable technology adaptable to infectious outbreaks. Highlights-A completely redesigned clinical proteomics platform increases throughput and precision while reducing costs.-27 biomarkers are differentially expressed between WHO severity grades for COVID-19.-The study highlights potential therapeutic targets that include complement factors, the coagulation system, inflammation modulators as well as pro-inflammatory signalling both upstream and downstream of interleukin 6.

show abstract

Section: Plasma Proteomes Provide Insights Into the Virulence Mechanimentioning

confidence: 99%

Section: Supplementary Informationmentioning

confidence: 99%

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

Messner

Demichev

Wendisch

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Leucine‐rich alpha‐2 glycoprotein (LRG), a novel acute phase protein, is an approximately 50 kDa glycoprotein containing repetitive sequences with a leucine‐rich motif 11 . The biological functions of LRG are remain unclear, however recent researches indicated that it can modulate angiogenesis, cell proliferation and differrentiation 11 . LRG is mainly secreted by the liver cells and neutrophils 12 .…”

Section: Introductionmentioning

confidence: 99%

Leucine‐rich alpha‐2 glycoprotein (LRG): A novel acute phase protein expressed in Stage 3 Grade C periodontitis before and after periodontal therapy

Yücel

Ballı

2020

Journal of Periodontology

View full text Add to dashboard Cite

Background Leucine‐rich alpha‐2 glycoprotein (LRG) is a novel acute phase protein involved in inflammation‐associated diseases and that considered to be induced by multiple proinflammatory cytokines. This study aimed to investigate gingival crevicular fluid (GCF) and serum levels of LRG, interleukin (IL)‐6 and tumor necrosis factor (TNF)‐α in patients with Stage 3 periodontitis before and after non‐surgical periodontal treatment. Methods Twenty‐five Stage 3 periodontitis and twenty‐five periodontally healthy individuals were enrolled in the study. Clinical periodontal measurements were recorded; periodontitis patients received non‐surgical periodontal treatment, and GCF and serum samples were obtained at baseline and at 6 weeks after treatment. LRG, IL‐6 and TNF‐α were determined by ELISA. Results GCF and serum LRG, IL‐6 and TNF‐α were significantly higher in periodontitis group than healthy controls (P < .001). A significant decrease in GCF and serum LRG, IL‐6 and TNF‐α was detected after periodontal treatment compared with baseline values of periodontitis patients (P < .001). Conclusion Our findings revealed that LRG expression was increased in Stage 3 periodontitis both locally and systemically, and non‐surgical periodontal therapy was effective in reducing LRG levels in GCF and serum of these patients.

show abstract

“…Then it was found to increase in response to mediators of acute phase response [4] and promote angiogenesis [7]. Thus LRG level was elevated in inflammatory diseases [12] and some cancers [13][14][15]. Recent study also found elevation of LRG is associated with arterial stiffness, endothelial dysfunction, peripheral vascular disease and CAD [16][17][18].…”

Section: Discussionmentioning

confidence: 99%

Expression and predictive value of leucine rich α-2 glycoprotein in ischemic heart disease

Gao¹,

Wu²,

Yin³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background : The expression and predictive value of leucine rich α-2 glycoprotein (LRG) in ischemic heart disease, including coronary artery disease (CAD), myocardial infarction (MI) and chronic total occlusion (CTO), remain unclear.Methods : A total of 231 patients were included and divided into 4 groups: control group (N=39), CAD group (N=73), MI group (N=67) and CTO group (N=52). LRG was determined and compared within groups. MI group was then divided into 2 subgroups according to LRG expression. The association between LRG expression and clinical characteristics, peak Troponin T (TNT), left ventricular ejection fraction (LVEF) and in-hospital stay was investigated.Results : LRG expression in MI group was significantly higher than that in control group (37.9±12.8 vs 25.3±8.9, P<0.001). LRG expression in CAD and CTO group were similar with that in control group (CAD vs Con, 23.1±6.8 vs 25.3±8.9, P=0.233; CTO vs Con, 22.0±7.8 vs 25.3±8.9, P=0.082). In MI group, patients with increased LRG had higher peak TNT (4.80 (2.34-10.0) vs 2.46 (0.89-4.98), P=0.002), lower LVEF (48.7±10.2 vs 54.8±8.4, P=0.009) and longer in-hospital stay (10.4±5.4 vs 8.0±2.9, P=0.027). Linear regression showed that LRG was independently associated with in-hospital stay. ROC curve showed the area of LRG under the curve (AUC) was 0.859.Conclusions : LRG expression was elevated in MI patients compared with controls, angiography confirmed CAD and CTO patients. In the MI subgroup, patients with elevated LRG had higher peak TNT, lower LVEF and longer in-hospital stay. Whether LRG is associated with major adverse cardiovascular events and long term prognosis needs further investigation.

show abstract

LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease

Abstract: View related articlesView Crossmark data Citing articles: 6 View citing articles LRG is a novel inflammatory marker clinically useful for the evaluation of disease activity in rheumatoid arthritis and inflammatory bowel disease

Cited by 51 publications

References 13 publications

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

Clinical classifiers of COVID-19 infection from novel ultra-high-throughput proteomics

Leucine‐rich alpha‐2 glycoprotein (LRG): A novel acute phase protein expressed in Stage 3 Grade C periodontitis before and after periodontal therapy

Expression and predictive value of leucine rich α-2 glycoprotein in ischemic heart disease

Contact Info

Product

Resources

About